JPWO2020193767A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020193767A5 JPWO2020193767A5 JP2021560302A JP2021560302A JPWO2020193767A5 JP WO2020193767 A5 JPWO2020193767 A5 JP WO2020193767A5 JP 2021560302 A JP2021560302 A JP 2021560302A JP 2021560302 A JP2021560302 A JP 2021560302A JP WO2020193767 A5 JPWO2020193767 A5 JP WO2020193767A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- tcr
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 96
- 108091008874 T cell receptors Proteins 0.000 claims description 42
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000012642 immune effector Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 102000011786 HLA-A Antigens Human genes 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102210042925 HLA-A*02:01 Human genes 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199432A JP2025024103A (ja) | 2019-03-27 | 2024-11-15 | Ｍａｇｅ ａ４ ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19165387.2A EP3714941A1 (en) | 2019-03-27 | 2019-03-27 | Mage-a4 tcrs |
| EP19165387.2 | 2019-03-27 | ||
| PCT/EP2020/058779 WO2020193767A1 (en) | 2019-03-27 | 2020-03-27 | Mage a4 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199432A Division JP2025024103A (ja) | 2019-03-27 | 2024-11-15 | Ｍａｇｅ ａ４ ｔ細胞受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527635A JP2022527635A (ja) | 2022-06-02 |
| JP2022527635A5 JP2022527635A5 (https=) | 2023-04-03 |
| JPWO2020193767A5 true JPWO2020193767A5 (https=) | 2023-04-03 |
| JP7590982B2 JP7590982B2 (ja) | 2024-11-27 |
Family
ID=66000958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560302A Active JP7590982B2 (ja) | 2019-03-27 | 2020-03-27 | Ｍａｇｅ ａ４ ｔ細胞受容体 |
| JP2024199432A Pending JP2025024103A (ja) | 2019-03-27 | 2024-11-15 | Ｍａｇｅ ａ４ ｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199432A Pending JP2025024103A (ja) | 2019-03-27 | 2024-11-15 | Ｍａｇｅ ａ４ ｔ細胞受容体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12344654B2 (https=) |
| EP (3) | EP3714941A1 (https=) |
| JP (2) | JP7590982B2 (https=) |
| CN (2) | CN118580335A (https=) |
| AU (1) | AU2020249598A1 (https=) |
| BR (1) | BR112021019066A2 (https=) |
| CA (1) | CA3134076A1 (https=) |
| CL (1) | CL2021002491A1 (https=) |
| CO (1) | CO2021012587A2 (https=) |
| DK (1) | DK3946621T3 (https=) |
| EA (1) | EA202192327A1 (https=) |
| ES (1) | ES3037919T3 (https=) |
| FI (1) | FI3946621T3 (https=) |
| HR (1) | HRP20250993T1 (https=) |
| HU (1) | HUE073008T2 (https=) |
| IL (1) | IL286569A (https=) |
| LT (1) | LT3946621T (https=) |
| MX (1) | MX2021011613A (https=) |
| PL (1) | PL3946621T3 (https=) |
| PT (1) | PT3946621T (https=) |
| RS (1) | RS67109B1 (https=) |
| SG (1) | SG11202110171QA (https=) |
| SI (1) | SI3946621T1 (https=) |
| SM (1) | SMT202500298T1 (https=) |
| WO (1) | WO2020193767A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| KR20220030933A (ko) * | 2019-05-08 | 2022-03-11 | 메디진 이뮤노테라피스 게엠바하 | 조작된 t 세포 |
| AU2021244594A1 (en) * | 2020-03-27 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | T cell receptors |
| CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
| CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| CN119546328A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| US20250382636A1 (en) | 2022-05-26 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| CN119569851A (zh) * | 2023-09-05 | 2025-03-07 | 香雪生命科学技术（广东）有限公司 | 针对magea4的高亲和力tcr |
| EP4635976A1 (en) * | 2024-04-19 | 2025-10-22 | Medigene Immunotherapies GmbH | Constant uni-tabs |
| WO2025219541A1 (en) * | 2024-04-19 | 2025-10-23 | Medigene Immunotherapies Gmbh | Constant uni-tabs |
| CN121342955B (zh) * | 2025-12-18 | 2026-03-06 | 中山大学孙逸仙纪念医院 | T细胞受体、融合蛋白、慢病毒、tcr-t细胞及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| IL286786B (en) * | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP2944652A1 (en) | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| PL3440105T3 (pl) * | 2016-04-08 | 2022-08-29 | Immunocore Limited | Receptory komórek t |
| SMT202100564T1 (it) * | 2016-04-08 | 2022-01-10 | Adaptimmune Ltd | Recettori di cellule t |
| CN110139873A (zh) | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| KR20220030933A (ko) | 2019-05-08 | 2022-03-11 | 메디진 이뮤노테라피스 게엠바하 | 조작된 t 세포 |
-
2019
- 2019-03-27 EP EP19165387.2A patent/EP3714941A1/en not_active Withdrawn
-
2020
- 2020-03-27 HU HUE20719942A patent/HUE073008T2/hu unknown
- 2020-03-27 FI FIEP20719942.3T patent/FI3946621T3/fi active
- 2020-03-27 EP EP20719942.3A patent/EP3946621B1/en active Active
- 2020-03-27 AU AU2020249598A patent/AU2020249598A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058779 patent/WO2020193767A1/en not_active Ceased
- 2020-03-27 BR BR112021019066A patent/BR112021019066A2/pt unknown
- 2020-03-27 US US17/441,861 patent/US12344654B2/en active Active
- 2020-03-27 PL PL20719942.3T patent/PL3946621T3/pl unknown
- 2020-03-27 JP JP2021560302A patent/JP7590982B2/ja active Active
- 2020-03-27 MX MX2021011613A patent/MX2021011613A/es unknown
- 2020-03-27 SG SG11202110171QA patent/SG11202110171QA/en unknown
- 2020-03-27 CA CA3134076A patent/CA3134076A1/en active Pending
- 2020-03-27 EP EP25177671.2A patent/EP4631516A2/en active Pending
- 2020-03-27 CN CN202410548142.5A patent/CN118580335A/zh active Pending
- 2020-03-27 HR HRP20250993TT patent/HRP20250993T1/hr unknown
- 2020-03-27 DK DK20719942.3T patent/DK3946621T3/da active
- 2020-03-27 LT LTEPPCT/EP2020/058779T patent/LT3946621T/lt unknown
- 2020-03-27 CN CN202080039452.4A patent/CN114126716B/zh active Active
- 2020-03-27 ES ES20719942T patent/ES3037919T3/es active Active
- 2020-03-27 SM SM20250298T patent/SMT202500298T1/it unknown
- 2020-03-27 SI SI202030648T patent/SI3946621T1/sl unknown
- 2020-03-27 EA EA202192327A patent/EA202192327A1/ru unknown
- 2020-03-27 PT PT207199423T patent/PT3946621T/pt unknown
- 2020-03-27 RS RS20250809A patent/RS67109B1/sr unknown
-
2021
- 2021-09-22 IL IL286569A patent/IL286569A/en unknown
- 2021-09-24 CO CONC2021/0012587A patent/CO2021012587A2/es unknown
- 2021-09-24 CL CL2021002491A patent/CL2021002491A1/es unknown
-
2024
- 2024-11-15 JP JP2024199432A patent/JP2025024103A/ja active Pending
-
2025
- 2025-05-23 US US19/217,625 patent/US20250346648A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020193767A5 (https=) | ||
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| JP2022109953A5 (https=) | ||
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| JP2024099850A5 (https=) | ||
| JP2024074801A5 (https=) | ||
| JP2020500523A5 (https=) | ||
| JP2023088937A (ja) | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 | |
| JP2020127426A5 (https=) | ||
| JP2020511936A5 (https=) | ||
| JP2020509767A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| FI4537839T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2021500406A5 (https=) | ||
| JP2021535900A5 (https=) | ||
| JP2021512637A5 (https=) | ||
| CN118317791A (zh) | 使用免疫细胞衔接蛋白和免疫调节剂的组合疗法 | |
| JP2019520038A5 (https=) | ||
| JP2022502015A5 (https=) | ||
| IL301995A (en) | Cells comprising t cell-antigen couplers and uses thereof | |
| JP2021501567A5 (https=) | ||
| TW202330589A (zh) | 治療 | |
| AU2019307905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| US20240301027A1 (en) | Treatment of mage-a4 positive cancer |